secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001193125-22-177791
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen EVP Chirfi Guindo to depart June 30; say-on-pay passes with 48% against
------------------------------------------------------------------------------

- Chirfi Guindo, EVP Global Product Strategy, leaves June 30, 2022 for a role outside Biogen.
- All 11 director nominees elected; Richard Mulligan received 77.4M for, 38.3M against.
- PwC ratified as 2022 auditor with 123.8M votes for and 2.3M against.
- Advisory say-on-pay approved: 60.1M for, 55.3M against (47.9% against), indicating shareholder concern.
- No other material changes reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000119312522177791/0001193125-22-177791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000119312522177791/d367101d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-177791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer